Calgary, AB – TheNewswire – October 12, 2023 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises of the following changes to its Board of Directors, effective October 11, 2023:
UI has appointed two new members to serve on the Company’s Board of Directors (the “Board”) to replace two Board members. Chief Ian Campbell and Anthony DeCristofaro have chosen to resign from the Company’s Board of Directors (the “Board”) in order to focus their time on family and other business opportunities. The Company thanks both Chief Campbell and Mr. DeCristofaro for their significant past guidance and commitment to helping UI in its formative stages.
James Duncan – Mr. Duncan is Director of Sales & Trading with Toronto based Independent Trading Group (ITG), and has been an active trader in the Canadian markets for 40 years, covering accounts from the EU, US and Canada, both retail and institutional. James has always been active in the trading community, serving Security Traders Associations (“STA”) across the country and was Chairman of the STA in the United States in 2004 as well as serving as chair of the CSTA in Canada. He founded the Bay Street Children’s foundation in 2000 and currently serves as its Chairman. James and his team have raised multiple millions for children’s charities in Toronto.
Dr. Dean Koumontzis – Dr. Koumontzis is an expert in orthopedic surgery and sports medicine with an emphasis on treating disorders of the elbow, shoulder and knee. He also serves as Director of the Bone Health Clinic at TOCA at Banner Health. He has been an invited faculty member of prestigious institutions across the country and has also served on many orthopedic and sports medicine committees throughout his career. His abstracts, manuscripts, and articles have been published in numerous scientific journals, magazines and textbooks, and his lectures and presentations have gained national and international recognition. Dr. Koumontzis has also served as team physician and orthopedic consultant at Arizona State University and has several years of non-profit Board experience, serving in a variety of positions. He is based in Scottsdale, Arizona, and is CEO of Bone Health Solutions, which creates educational web based platforms and clinical system management solutions.
Nick Karos, UI CEO, noted “UI is pleased to welcome James and Dean to our Board, and I look forward to working with them in advancing our addiction treatment mission. I also would like to recognize and thank Chief Campbell and Anthony for their past service to UI.”
The Board appointments are subject to the required approvals of the TSX Venture Exchange.
About Universal Ibogaine Inc.
UI is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that treatment protocol globally through planned future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre (located near Winnipeg, Manitoba) that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such as “plans”, “planned”, “expect”, “project”, “intends”, “intended” “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ”could” occur. The forward-looking statements and information are based on certain key expectations and assumptions made by UI. Although UI believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because UI can give no assurance that they will prove to be correct.
Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks, which include, but are not limited to, risks that required regulatory approvals are not obtained. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable by UI at the time of preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on forward-looking information, which speaks only to conditions as of the date hereof. UI does not undertake any obligation to release publicly any revisions to forward-looking information contained herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.
For further information:
Nick Karos, CEO
Universal Ibogaine Inc.
612-309-3527
